{
    "clinical_study": {
        "@rank": "43756", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give SU5416 to\n      HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth\n      of KS tumors."
        }, 
        "brief_title": "Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in\n      33% increments. Study drug is administered as a twice-weekly intravenous injection for 4\n      weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416\n      in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable\n      toxicity or tumor progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are at least 18 years old.\n\n          -  Are HIV-positive.\n\n          -  Have KS with at least 5 skin lesions.\n\n          -  Have been in stable condition for at least 6 weeks prior to study entry, if receiving\n             antiretroviral therapy.\n\n          -  Agree to use effective methods of birth control during the study.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Have had surgery within 4 weeks of study entry.\n\n          -  Have taken certain medications, including therapy for KS, within 3 weeks prior to\n             study entry.\n\n          -  Have pulmonary KS (KS in your lungs).\n\n          -  Have certain serious medical conditions, including liver or kidney problems, certain\n             infections, and certain cancers.\n\n          -  Are allergic to Cremophor.\n\n          -  Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or\n             immunotherapy).\n\n          -  Are pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002226", 
            "org_study_id": "294A", 
            "secondary_id": "5416.003"
        }, 
        "intervention": {
            "intervention_name": "SU5416", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "SU 5416", 
                "Antineoplastic Agents"
            ]
        }, 
        "keyword": [
            "Skin Neoplasms", 
            "Sarcoma, Kaposi", 
            "Antineoplastic Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900951793"
                    }, 
                    "name": "UCLA Care Ctr / Ctr for Hlth Sciences"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Norris Cancer Ctr / USC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "Saint Francis Mem Hosp / HIV Care Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York Univ Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Gill P, Arasteh K, Jacobs M, Friedman-Kiel A, Miles S, Gracey S, Hannah A, Langecker P. A multicenter, dose-escalating study in patients with AIDS-related Kaposi's Sarcoma 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002226"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SUGEN", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {
        "New York Univ Med Ctr": "40.714 -74.006", 
        "Norris Cancer Ctr / USC": "34.052 -118.244", 
        "Saint Francis Mem Hosp / HIV Care Unit": "37.775 -122.419", 
        "UCLA Care Ctr / Ctr for Hlth Sciences": "34.052 -118.244"
    }
}